Tarlatamab in the Real World

Tarlatamab has changed the treatment landscape for relapsed small-cell lung cancer (SCLC). However, patients treated in routine practice are often older, frailer or have more complex disease than those enrolled in clinical trials. A multicentre US study led by Alissa J. Cooper therefore assessed the effectiveness and safety of tarlatamab in a real-world population, with particular attention to patients who would have been excluded from pivotal trials. The study was published online in March 2026 in Lung Cancer.